TLDR:
- Paris-based Metyos, a medtech startup, raises €2.3M in pre-seed funding led by Cenitz with participation from KIMA Ventures, Advans Lab, and Bpifrance.
- Metyos aims to transform chronic kidney disease (CKD) management with its biowearable sensor and platform, providing real-time biomarker readings for doctors to monitor kidney function and empower patients in self-care.
Paris-based Metyos, a medtech startup focused on tackling chronic kidney disease (CKD), has recently secured €2.3M in pre-seed funding. The investment was led by Cenitz, with participation from KIMA Ventures, Advans Lab, and Bpifrance, along with support from doctors, health insurance angels, and business leaders from Implicity, Deepmind, and Nabla. The funding will be utilized to advance its wearable technology, focusing on progressing through clinical trials in preparation for FDA clearance.
Metyos aims to transform CKD management with its biowearable sensor and platform, providing real-time biomarker readings for doctors to monitor kidney function and empower patients in self-care. The company, founded by CEO Alexandre Boulanger and CTO Olga Chashchina, seeks to proactively manage symptoms and slow disease progression, benefiting both patients and healthcare systems. With CKD affecting 10% of the population and being a major cause of death, Metyos aims to transform the lives of over 800 million CKD patients globally.
CEO Alexandre Boulanger, a serial medtech entrepreneur, and Dr. Olga Chashchina, with expertise in biosensors, lead Metyos in its mission to move healthcare towards proactive disease management. The company is currently actively recruiting participants for clinical trials to enhance and validate its biowearable technology, with a vision to offer better, proactive care for all in the future.
